真实世界研究揭示HER2低表达并非独立预后因素，而是与临床病理特征相关。乳腺癌是全球女性最常见的恶性肿瘤之一。近年来，HER2低表达（HER2-low）乳腺癌作为一种新的治疗亚型备受关注。HER2-low乳腺癌是指HER2免疫组化（IHC）表达为1+ ...

In Europe, approximately 531,000 breast cancer patients are diagnosed annually, with around 141,000 deaths, and around half of all cases would fall under the HER2-low classification, split between ...

The following is a summary of “HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TN,” published in the ...

The top-line results of DESTINY Breast-04 are impressive - in patients with HER2-low metastatic breast cancer who received multiple lines of prior treatment, Enhertu (trastuzumab deruxtecan ...

Enhertu is approved for HR-positive, HER2-low or -ultralow metastatic breast cancer, expanding treatment options for these patients. DESTINY-Breast06 trial showed Enhertu reduced disease progression ...

One of the major breakthroughs in the field of breast cancer was a new classification of the disease, called HER2-low, referring to the presence of the human epidermal growth factor receptor 2 protein ...

Due to the differences in HER2 gene and protein expression levels, they are clinically classified into HER2 zero-expression breast cancer, low-expression breast cancer and high-expression breast ...

中山大学附属第一医院的研究人员为精准诊断 HER2-low 乳腺癌，开展相关研究，构建预测模型，助力临床决策。 乳腺癌是全球女性健康的 “头号杀手”，HER2 阳性肿瘤约占 15 - 20%，其余大多为 HER2 阴性肿瘤，其中 HER2-low 亚型占比达 40.4%。以往 HER2 阴性乳腺癌治疗 ...

A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.